Kindness for Kidneys International Received an
Honorable Mention
NEW
YORK and WOONSOCKET,
R.I., May 20, 2022 /PRNewswire/ -- Lyfebulb, a
patient-empowerment platform that connects patients with industry
experts to support user-driven innovation, and CVS Kidney
Care®, a CVS Health® (NYSE: CVS)
company, are excited to announce that OmniLife was selected as the
winner, and Kindness for Kidneys International received an
honorable mention, at the 2022 Lyfebulb–CVS
Kidney Care® Innovation Challenge:
Accelerating Innovations in Kidney Disease to Improve Health Equity
and Outcomes.
Lyfebulb and CVS Kidney Care Announce
OmniLIfe as Winner of 2022 Innovation Challenge in Kidney
Disease
"True equity means everyone has the opportunity to attain their
full health potential," said Jesse
Roach, MD, Senior Medical Director, Health Equity at CVS
Kidney Care®. "We applaud OmniLife, Kindness for Kidneys
and the other challenge finalists for their efforts to
address barriers to care that make
preventing and managing kidney disease difficult."
OmniLife was represented by Co-Founder and CEO Dalton Shaull and will receive a $25,000 monetary award to further develop its
end-to-end communication and collaboration solution purpose-built
for transplant teams to automate the intake and patient referral
management process to provide better outcomes, reduce costs
and create an optimal experience for clinicians and their
patients.
Additionally, the judges awarded Kindness for Kidneys
International, represented by Founder and Executive Director
Sharron Rouse, honorable mention for
its dedication to educating, encouraging, and empowering kidney
warriors and their families.
The 2022 Innovation Challenge took place in Austin, TX over two days on May 18-19. Before a panel of independent judges,
each of the ten finalists pitched solutions for bringing equitable
care to kidney disease patients. Finalists also had the
opportunity to listen to keynotes from leaders in the kidney and
health care space, as well as community health leaders in
Austin, and take part in two small
group learning sessions.
"The level of innovation presented by each finalist was
impressive and inspiring, and we look forward to seeing their
ventures grow and help to address the disparities that so often
prevent access to care and negatively impact health outcomes for
those in the CKD and ESRD community," said Karin Hehenberger, MD, Ph.D., Founder and CEO of
Lyfebulb. "As a person living with chronic kidney disease and
having gone through a living donor kidney transplant, I was
especially excited and encouraged by the potential impact these
innovations will have on the patient community."
To continue their commitment to patient entrepreneurship and to
raising awareness about health inequities among those in the CKD
and ESRD community, Lyfebulb and CVS Kidney
Care® will be hosting a Fireside Chat with
Dalton Shaull and Sharron Rouse, jury member Jennifer Miller of CVS Kidney
Care®, and key opinion leader, Jesse Roach, MD, of CVS Kidney Care®,
on Wednesday, June 1 at 4 p.m. EST. This virtual discussion is open to
all community members, and more information can be found on
Transplantlyfe.com/webinars.
To learn more about CVS Kidney Care®'s work to
address equitable health care, visit cvskidneycare.com.
About CVS Kidney Care®
CVS Kidney
Care® is reimagining the future of kidney
health – because patients deserve care that helps them live on
their own terms. Our unmatched patient insights, grounded in the
connectivity of CVS Health®, link data and clinical
knowledge to create a personalized approach that breaks down
barriers to care, including systemic barriers that have led to
disparities in kidney health. Our end-to-end approach is flexible
and customizable to help support a truly patient-centered
experience. No matter where people are in their kidney-health
journey, we help them connect to an integrated network of options
that make care easier to understand, more accessible, and suited to
their needs.
We are changing kidney care as we know it because the more than
37 million Americans living with chronic kidney disease deserve
more than twentieth-century solutions. Learn more
at cvskidneycare.com.
About Lyfebulb
Lyfebulb is an innovation accelerator that bridges the gap between
patient communities and the healthcare industry by working directly
with patients and care partners to generate insights and build new
solutions to reduce the burden of living with chronic disease.
Lyfebulb operates across 12 disease states and counting. For more
information, see Lyfebulb.com, TransplantLyfe.com,
IBDLyfe.com, Instagram, LinkedIn, Twitter, Facebook,
and Karin Hehenberger LinkedIn.
For more information:
CVS Health Contact:
KC Sledd
Senior Manager, Corporate Communications
Phone: +1 401 328 5361
Email: kristin.sledd@cvshealth.com
Lyfebulb Contact:
Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb
Phone: + 1 917-575-0210
Email: karin@lyfebulb.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/omnilife-named-winner-of-the-2022-lyfebulbcvs-kidney-care-innovation-challenge-301551881.html
SOURCE Lyfebulb